Antibody to the gp120 V1/V2 loops and CD4+and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia

Journal of Immunology

Volumn 193, Issue 12, 2014, Pages 6172-6183

  Gordon, Shari N ^a   Doster, Melvin N ^a   Kines, Rhonda C ^a   Keele, Brandon F ^b   Brocca Cofano, Egidio ^a   Guan, Yongjun ^c   Pegu, Poonam ^a   Liyanage, Namal P M ^a   Vaccari, Monica ^a   Cuburu, Nicolas ^a   Buck, Christopher B ^a   Ferrari, Guido ^d   Montefiori, David ^d   Piatak, Michael ^b   Lifson, Jeffrey D ^b   Xenophontos, Anastasia M ^a   Venzon, David ^a   Robert Guroff, Marjorie ^a   Graham, Barney S ^e   Lowy, Douglas R ^a   Schiller, John T ^a   Franchini, Genoveffa ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 VACCINE; HUMAN PAPILLOMAVIRUS PSEUDOVIRION VACCINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE; DNA VACCINE; PEPTIDE FRAGMENT; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GAG GENE; GAG PRO GENE; GENE EXPRESSION; GP120 GENE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; NEF GENE; NONHUMAN; PROTEIN EXPRESSION; REV GENE; SIMIAN IMMUNODEFICIENCY VIRUS; TAT GENE; VACCINATION; VIREMIA; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; WART VIRUS; ALPHAPAPILLOMAVIRUS; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DISEASE MODEL; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MOLECULAR GENETICS; MUCOSA; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE SUBPOPULATION; VAGINA; VIROLOGY;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; GENETIC VECTORS; LYMPHOCYTE DEPLETION; MACACA MULATTA; MOLECULAR SEQUENCE DATA; MUCOUS MEMBRANE; PEPTIDE FRAGMENTS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTE SUBSETS; VACCINATION; VACCINES, DNA; VAGINA; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 84916898537     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401504     Document Type: Article

References (55)

1. Mikell, I., D. N. Sather, S. A. Kalams, M. Altfeld, G. Alter, and L. Stamatatos. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7: e1001251.
2. Scheid, J. F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T. Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333: 1633-1637.
3. Pitisuttithum, P., P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, and K. Choopanya, Bangkok Vaccine Evaluation Group. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194: 1661-1671.
4. Flynn, N. M., D. N. Forthal, C. D. Harro, F. N. Judson, K. H. Mayer, and M. F. Para, rgp120 HIV Vaccine Study Group. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191: 654-665.
5. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
6. Gray, G. E., M. Allen, Z. Moodie, G. Churchyard, L. G. Bekker, M. Nchabeleng, K. Mlisana, B. Metch, G. de Bruyn, M. H. Latka, et al; HVTN 503/Phambili study team. 2011. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of- concept phase 2b study. Lancet Infect. Dis. 11: 507-515.
7. Hammer, S. M., M. E. Sobieszczyk, H. Janes, S. T. Karuna, M. J. Mulligan, D. Grove, B. A. Koblin, S. P. Buchbinder, M. C. Keefer, G. D. Tomaras, et al; HVTN 505 Study Team. 2013. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369: 2083-2092.
8. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
9. Haynes, B. F., P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, et al. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366: 1275-1286.
10. Hope, T. J. 2011. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nat. Med. 17: 1195-1197.
11. Sui, Y., S. Gordon, G. Franchini, and J. A. Berzofsky. 2013. Nonhuman primate models for HIV/AIDS vaccine development. Curr. Protoc. Immunol 102:Unit 12.14.
12. Qureshi, H., Z. M. Ma, Y. Huang, G. Hodge, M. A. Thomas, J. DiPasquale, V. DeSilva, L. Fritts, A. J. Bett, D. R. Casimiro, et al. 2012. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J. Virol. 86: 2239-2250.
13. Van Rompay, K. K., K. Abel, J. R. Lawson, R. P. Singh, K. A. Schmidt, T. Evans, P. Earl, D. Harvey, G. Franchini, J. Tartaglia, et al. 2005. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defic. Syndr. 38: 124-134.
14. Reynolds, M. R., A. M. Weiler, S. M. Piaskowski, M. Piatak, Jr., H. T. Robertson, D. B. Allison, A. J. Bett, D. R. Casimiro, J. W. Shiver, N. A. Wilson, et al. 2012. A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge. Vaccine 30: 4465-4475.
15. Lai, L., S. Kwa, P. A. Kozlowski, D. C. Montefiori, G. Ferrari, W. E. Johnson, V. Hirsch, F. Villinger, L. Chennareddi, P. L. Earl, et al. 2011. Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J. Infect. Dis. 204: 164-173.
16. Barouch, D. H., J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. SanMiguel, M. S. Seaman, G. Ferrari, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
17. Xiao, P., L. J. Patterson, S. Kuate, E. Brocca-Cofano, M. A. Thomas, D. Venzon, J. Zhao, J. DiPasquale, C. Fenizia, E. M. Lee, et al. 2012. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J. Virol. 86: 4644-4657.
18. Hansen, S. G., J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne-Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527.
19. Patel, V., R. Jalah, V. Kulkarni, A. Valentin, M. Rosati, C. Alicea, A. von Gegerfelt, W. Huang, Y. Guan, B. F. Keele, et al. 2013. DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc. Natl. Acad. Sci. USA 110: 2975-2980.
20. Vaccari, M., B. F. Keele, S. E. Bosinger, M. N. Doster, Z. M. Ma, J. Pollara, A. Hryniewicz, G. Ferrari, Y. Guan, D. N. Forthal, et al. 2013. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J. Virol. 87: 3538-3548.
21. Rerks-Ngarm, S., R. M. Paris, S. Chunsutthiwat, N. Premsri, C. Namwat, C. Bowonwatanuwong, S. S. Li, J. Kaewkungkal, R. Trichavaroj, N. Churikanont, et al. 2013. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E. J. Infect. Dis. 207: 1195-1205.
22. Jin, X., D. E. Bauer, S. E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C. E. Irwin, J. T. Safrit, J. Mittler, L. Weinberger, et al. 1999. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189: 991-998.
23. Schmitz, J. E., M. J. Kuroda, S. Santra, V. G. Sasseville, M. A. Simon, M. A. Lifton, P. Racz, K. Tenner-Racz, M. Dalesandro, B. J. Scallon, et al. 1999. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857-860.
24. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
25. Borrow, P., H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. Oldstone. 1994. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68: 6103-6110.
26. Price, D. A., P. J. Goulder, P. Klenerman, A. K. Sewell, P. J. Easterbrook, M. Troop, C. R. Bangham, and R. E. Phillips. 1997. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc. Natl. Acad. Sci. USA 94: 1890-1895.
27. Leslie, A. J., K. J. Pfafferott, P. Chetty, R. Draenert, M. M. Addo, M. Feeney, Y. Tang, E. C. Holmes, T. Allen, J. G. Prado, et al. 2004. HIV evolution: CTL escape mutation and reversion after transmission. Nat. Med. 10: 282-289.
28. Borrow, P., H. Lewicki, X. Wei, M. S. Horwitz, N. Peffer, H. Meyers, J. A. Nelson, J. E. Gairin, B. H. Hahn, M. B. Oldstone, and G. M. Shaw. 1997. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3: 205-211.
29. Hansen, S. G., J. B. Sacha, C. M. Hughes, J. C. Ford, B. J. Burwitz, I. Scholz, R. M. Gilbride, M. S. Lewis, A. N. Gilliam, A. B. Ventura, et al. 2013. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science 340: 1237874.
30. Hansen, S. G., M. Piatak, Jr., A. B. Ventura, C. M. Hughes, R. M. Gilbride, J. C. Ford, K. Oswald, R. Shoemaker, Y. Li, M. S. Lewis, et al. 2013. Immune clearance of highly pathogenic SIV infection. Nature 502: 100-104.
31. Roberts, J. N., C. B. Buck, C. D. Thompson, R. Kines, M. Bernardo, P. L. Choyke, D. R. Lowy, and J. T. Schiller. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13: 857-861.
32. Çuburu, N., B. S. Graham, C. B. Buck, R. C. Kines, Y. Y. Pang, P. M. Day, D. R. Lowy, and J. T. Schiller. 2012. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J. Clin. Invest. 122: 4606-4620.
33. Graham, B. S., R. C. Kines, K. S. Corbett, J. Nicewonger, T. R. Johnson, M. Chen, D. LaVigne, J. N. Roberts, N. Cuburu, J. T. Schiller, and C. B. Buck. 2010. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol. 3: 475-486.
34. Schiller, J. T., and D. R. Lowy. 2012. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 10: 681-692.
35. Rudolf, M. P., S. C. Fausch, D. M. Da Silva, and W. M. Kast. 2001. Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J. Immunol. 166: 5917-5924.
36. Lenz, P., P. M. Day, Y. Y. Pang, S. A. Frye, P. N. Jensen, D. R. Lowy, and J. T. Schiller. 2001. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166: 5346-5355.
37. Gordon, S. N., R. C. Kines, G. Kutsyna, Z. M. Ma, A. Hryniewicz, J. N. Roberts, C. Fenizia, R. Hidajat, E. Brocca-Cofano, N. Cuburu, et al. 2012. Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J. Immunol. 188: 714-723.
38. Franchini, G., M. Robert-Guroff, J. Tartaglia, A. Aggarwal, A. Abimiku, J. Benson, P. Markham, K. Limbach, G. Hurteau, J. Fullen, et al. 1995. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11: 909-920.
39. Pegu, P., M. Vaccari, S. Gordon, B. F. Keele, M. Doster, Y. Guan, G. Ferrari, R. Pal, M. G. Ferrari, S. Whitney, et al. 2013. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV (mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J. Virol. 87: 1708-1719.
40. Pal, R., D. Venzon, N. L. Letvin, S. Santra, D. C. Montefiori, N. R. Miller, E. Tryniszewska, M. G. Lewis, T. C. VanCott, V. Hirsch, et al. 2002. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A∗01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J. Virol. 76: 292-302.
41. Buck, C. B., D. V. Pastrana, D. R. Lowy, and J. T. Schiller. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78: 751-757.
42. Roederer, M., J. L. Nozzi, and M. C. Nason. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79: 167-174.
43. Pollara, J., L. Hart, F. Brewer, J. Pickeral, B. Z. Packard, J. A. Hoxie, A. Komoriya, C. Ochsenbauer, J. C. Kappes, M. Roederer, et al. 2011. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79: 603-612.
44. Montefiori, D. C. 2005. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr. Protoc. Immunol: Chapter 12: Unit 12.
45. Lee, E. M., H. K. Chung, J. Livesay, J. Suschak, L. Finke, L. Hudacik, L. Galmin, B. Bowen, P. Markham, A. Cristillo, and R. Pal. 2010. Molecular methods for evaluation of virological status of nonhuman primates challenged with simian immunodeficiency or simian-human immunodeficiency viruses. J. Virol. Methods 163: 287-294.
46. Romano, J. W., K. G. Williams, R. N. Shurtliff, C. Ginocchio, and M. Kaplan. 1997. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26: 15-28.
47. Liu, J., B. F. Keele, H. Li, S. Keating, P. J. Norris, A. Carville, K. G. Mansfield, G. D. Tomaras, B. F. Haynes, D. Kolodkin-Gal, et al. 2010. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J. Virol. 84: 10406-10412.
48. Keele, B. F., E. E. Giorgi, J. F. Salazar-Gonzalez, J. M. Decker, K. T. Pham, M. G. Salazar, C. Sun, T. Grayson, S. Wang, H. Li, et al. 2008. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105: 7552-7557.
49. Keele, B. F., H. Li, G. H. Learn, P. Hraber, E. E. Giorgi, T. Grayson, C. Sun, Y. Chen, W. W. Yeh, N. L. Letvin, et al. 2009. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J. Exp. Med. 206: 1117-1134.
50. Schmitz, J. E., M. A. Simon, M. J. Kuroda, M. A. Lifton, M. W. Ollert, C. W. Vogel, P. Racz, K. Tenner-Racz, B. J. Scallon, M. Dalesandro, et al. 1999. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154: 1923-1932.
51. Haase, A. T. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62: 127-139.
52. Gillgrass, A. E., A. A. Ashkar, K. L. Rosenthal, and C. Kaushic. 2003. Prolonged exposure to progesterone prevents induction of protective mucosal responses following intravaginal immunization with attenuated herpes simplex virus type 2. J. Virol. 77: 9845-9851.
53. Roberts, J. N., R. C. Kines, H. A. Katki, D. R. Lowy, and J. T. Schiller. 2011. Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J. Natl. Cancer Inst. 103: 737-743.
54. Strbo, N., M. Vaccari, S. Pahwa, M. A. Kolber, M. N. Doster, E. Fisher, L. Gonzalez, D. Stablein, G. Franchini, and E. R. Podack. 2013. Cutting edge: novel vaccination modality provides significant protection against mucosal infection by highly pathogenic simian immunodeficiency virus. J. Immunol. 190: 2495-2499.
55. Pollara, J., M Bonsignori, M. A. Moody, P. Liu, S. M. Alam, K. K. Hwang, T. C. Gurley, D. M. Kozink, L. C. Armand, D. J. Marshall, et al. 2014. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J. Virol. 88: 7715-7726.